Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

'Insufficient evidence' that NSAIDs should not be used for COVID-19

Patients can use ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) to treat the symptoms of COVID-19, an MHRA advisory body and Nice have said.

Last month (March 17), NHS England asked the Commission of Human Medicines (CHM) Expert Working Group on COVID-19 and the National Institute for health and Care Excellence (Nice) to review existing evidence on the use of NSAIDs, including ibuprofen, to treat symptoms of COVID-19.

Publishing its findings earlier this week (April 14), the CHM said: “There is currently insufficient evidence to establish a link between the use of ibuprofen, or other NSAIDs and susceptibility to contracting COVID-19 or the worsening of its symptoms.”

Nice said 13 studies had been “obtained and assessed for relevance”, but “none were suitable for inclusion”.

“This means that no evidence from published scientific studies was found to determine whether acute use of NSAIDs is related to increased risk of developing COVID-19 or increased risk of a more severe illness,” the organisation said in a statement published on Tuesday (April 14).

Background to review

The CHM and Nice were last month asked to analyse existing evidence to understand if it is safe to use ibuprofen to alleviate symptoms of COVID-19.

NHS England medical director professor Stephen Powis made the request following concerns raised earlier in March by the French health minister Olivier Véran, who advised against the use of NSAIDs to treat COVID-19 symptoms, as he feared these medicines could worsen the infection.

On March 17, professor Powis issued an alert to all clinical staff. In this, he stated said that while there appeared “to be no evidence that NSAIDs increase the chance of acquiring COVID-19”, paracetamol should be used over these drugs to treat COVID-19 symptoms, such as fever or headache, until more information was available.

Following the CHM and Nice findings, this position has now been revised to say that patients who have or are showing symptoms of COVID-19 can use paracetamol or ibuprofen to treat symptoms of the virus.

Last month, the General Pharmaceutical Council (GPhC) said pharmacies can split “larger packs of paracetamol” to sell to the public, as it understands it has been difficult to obtain the OTC analgesic from wholesalers during the pandemic.

The GPhC told C+D today (March 16) that pharmacists can also split larger packs of ibuprofen, if necessary.

Is there a shortage of Ibuprofen due to COVID-19?

Related Content

Topics


         
Accreditation & Recognition Panel Members
Nationwide
£ Remuneration

Apply Now
UsernamePublicRestriction

Register

CD006447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel